Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B Cell Lymphoma: Report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

被引：72

作者：

Sirvent, Anne ^{[1
]}

Dhedin, Nathalie ^{[2
]}

Michallet, Mauricette ^{[3
]}

Mounier, Nicolas ^{[1
]}

Faucher, Catherine ^{[4
]}

Yakoub-Agha, Ibrahim ^{[5
]}

Mohty, Mohamad ^{[6
]}

Robin, Marie ^{[7
]}

Tabrizi, Reza ^{[8
]}

Clement, Laurence ^{[9
]}

Bilger, Karin ^{[10
]}

Larosa, Fabrice ^{[11
]}

Contentin, Nathalie ^{[12
]}

Huyn, Anne ^{[13
]}

Francois, Sylvie ^{[14
]}

Bulabois, Claude-Eric ^{[15
]}

Ceballos, Patrice ^{[16
]}

Bourrhis, Jean-Henri ^{[17
]}

Buzyn, Agnes ^{[18
]}

Cornillon, Jerome ^{[19
]}

Guillerm, Gaelle ^{[20
]}

de Revel, Thierry ^{[21
]}

Bay, Jacques-Olivier ^{[22
]}

Guilhot, Francois ^{[23
]}

Milpied, Noel ^{[7
,8
]}

机构：

[1] Hop Archet, F-06202 Nice, France

[2] Hosp La Pitie Salpetriere, Paris, France

[3] Hop Edouard Herriot, Lyon, France

[4] Inst J Paoli I Calmettes, F-13009 Marseille, France

[5] CHU Huriez, Lille, France

[6] CHU Hotel Dieu, Nantes, France

[7] Hosp St Louis, Paris, France

[8] CHU Haut Leveque, Bordeaux, France

[9] Hosp Brabois, Nancy, France

[10] Hosp Hautepierre, Strasbourg, France

[11] Hosp J Minjoz, Besancon, France

[12] Ctr Henri Becquerel, F-76038 Rouen, France

[13] Hosp Purpan, Toulouse, France

[14] CHU Angers, Angers, France

[15] CHU Michallon, Grenoble, France

[16] Hosp Lapeyronie, Montpellier, France

[17] Inst Gustave Roussy, Villejuif, France

[18] Hop Necker Enfants Malad, Paris, France

[19] Inst Cancerol Loire, St Etienne, France

[20] CHU Augustin Morvan, Brest, France

[21] Hosp Percy, Clamart, France

[22] Ctr Jean Perrin, Clermont Ferrand, France

[23] Hosp Jean Bernard, Poitiers, France

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2010年 / 16卷 / 01期

关键词：

Non-Hodgkin's lymphoma; Reduced-intensity conditioning regimen; Allogeneic stem cell transplantation; NON-HODGKINS-LYMPHOMA; BONE-MARROW-TRANSPLANTATION; POSITRON-EMISSION-TOMOGRAPHY; HIGH-DOSE THERAPY; AUTOLOGOUS TRANSPLANTATION; AGGRESSIVE LYMPHOMA; SALVAGE THERAPY; CHEMOTHERAPY; DISEASE; RITUXIMAB;

D O I：

10.1016/j.bbmt.2009.09.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have a very poor prognosis. However, they may achieve long-term survival by undergoing allogeneic stem cell transplantation (SCT). The purpose of this study was to assess the outcome of all adult patients with DLBCL whose treatment included a reduced-intensity conditioning (RIC) regimen for allogeneic SCT and whose data were reported in the French Society of Marrow Transplantation and Cellular Therapy registry. Sixty-eight patients (median age: 48 years) were transplanted from October 1998 to January 2007. They had received a median of 2 regimens of therapy prior to allogeneic SCT, and 54 (79%) had already undergone SCT. Prior to transplantation, 32 patients (47%) were in complete remission (CR). For all patients but I, conditioning regimens were based on fludarabine (Flu), which was combined with other chemotherapy drugs in 50 cases (74%) and with total body irradiation (TBI) in 17 (25%). For 56 patients (82%), the donor was an HLA-matched sibling, and peripheral blood was the most widely used source of stem cells (57 patients, 84%). With a median follow-up of 49 months, estimated 2-year overall survival (OS), progression-free survival (PFS), and the cumulative incidence of relapse were 49%, 44%, and 41%, respectively. The I-year cumulative incidence of nonrelapse mortality (NRM) was 23%. According to multivariate analysis, the patients in CR before transplantation had a significantly longer PFS and a lower CI of relapse than patients transplanted during partial remission or stable or progressive disease. These results suggest that reduced-intensity allergenic transplantation is an attractive therapeutic option for patients with high-risk DLBCL. Bid Blood Marrow Transplant 16: 78-85 (2010) (C) 2010 American Society for Blood and Marrow Transplantation

引用

页码：78 / 85

页数：8

共 39 条

[1] Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation [J].

Alousi, Amin M. ;

Saliba, Rima M. ;

Okoroji, Grace-Julia ;

Macapinlac, Homer A. ;

Hosing, Chitra ;

Korbling, Martin ;

Samuels, Barry I. ;

Popat, Uday ;

Kebriaei, Partow ;

Anderlini, Paolo ;

Qazilbash, Muzaffar H. ;

de Lima, Marcos ;

Giralt, Sergio A. ;

Champlin, Richard E. ;

Khouri, Issa F. .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (05) :786-792

[2] Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: Importance of histology for outcome [J].

Armand, Philippe ;

Kim, Haesook T. ;

Ho, Vincent T. ;

Cutler, Corey S. ;

Koreth, John ;

Antin, Joseph H. ;

LaCasce, Ann S. ;

Jacobsen, Eric D. ;

Fisher, David C. ;

Brown, Jennifer R. ;

Canellos, George P. ;

Freedman, Arnold S. ;

Soiffer, Rohert J. ;

Alyea, Edwin P. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (04) :418-425

[3] Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation [J].

Bishop, M. R. ;

Dean, R. M. ;

Steinberg, S. M. ;

Odom, J. ;

Pavletic, S. Z. ;

Chow, C. ;

Pittaluga, S. ;

Sportes, C. ;

Hardy, N. M. ;

Gea-Banacloche, J. ;

Kolstad, A. ;

Gress, R. E. ;

Fowler, D. H. .

ANNALS OF ONCOLOGY, 2008, 19 (11) :1935-1940

[4] High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation [J].

Buser, A. S. ;

Stern, M. ;

Bucher, C. ;

Arber, C. ;

Heim, D. ;

Halter, J. ;

Meyer-Monard, S. ;

Stussi, G. ;

Lohri, A. ;

Ghielmini, M. ;

Tichelli, A. ;

Passweg, J. R. ;

Gratwohl, A. .

BONE MARROW TRANSPLANTATION, 2007, 39 (06) :335-340

[5] Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma [J].

Carella, AM ;

Cavaliere, M ;

Lerma, E ;

Ferrara, R ;

Tedeschi, L ;

Romanelli, A ;

Vinci, M ;

Pinotti, G ;

Lambelet, P ;

Loni, C ;

Verdiani, S ;

De Stefano, F ;

Valbonesi, M ;

Corsetti, MT .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) :3918-3924

[6] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[7] Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome [J].

Corradini, P. ;

Dodero, A. ;

Farina, L. ;

Fanin, R. ;

Patriarca, F. ;

Miceli, R. ;

Matteucci, P. ;

Bregni, M. ;

Scime, R. ;

Narni, F. ;

Pogliani, E. ;

Locasciulli, A. ;

Milani, R. ;

Carniti, C. ;

Bacigalupo, A. ;

Rambaldi, A. ;

Bonifazi, F. ;

Olivieri, A. ;

Gianni, A. M. ;

Tarella, C. .

LEUKEMIA, 2007, 21 (11) :2316-2323

[8]

Dhedin N, 1999, BRIT J HAEMATOL, V107, P154

[9]

DODERO A, 2007, BLOOD, V110, pA3039

[10] Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma [J].

Doocey, RT ;

Toze, CL ;

Connors, JM ;

Nevill, TJ ;

Gascoyne, RD ;

Barnett, MJ ;

Forrest, DL ;

Hogge, DE ;

Lavoie, JC ;

Nantel, SH ;

Shepherd, JD ;

Sutherland, HJ ;

Voss, NJ ;

Smith, CA ;

Song, KW .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) :223-230

← 1 2 3 4 →